Role of Serotonin<sub>2A</sub> and Serotonin<sub>2B/2C</sub> Receptor Subtypes in the Control of Accumbal and Striatal Dopamine Release Elicited In Vivo by Dorsal Raphe Nucleus Electrical Stimulation
Tóm tắt
Từ khóa
Tài liệu tham khảo
Ashby C.H.J, 1996, Differential effect of the 5‐HT2B/2C receptor antagonist SB 200646 and the selective 5‐HT2A antagonist MDL 100907 on midbrain dopamine (DA) neurons in rats : an electrophysiological study., Soc. Neurosci. Abstr., 22, 1323
De Deurwaerdère P., 1998, Opposite change of in vivo dopamine release in the rat nucleus accumbens and striatum that follows electrical stimulation of dorsal raphe nucleus : role of 5‐HT3 receptors., J. Neurosci., 18, 6528, 10.1523/JNEUROSCI.18-16-06528.1998
Deutch A.Y., 1991, Mechanisms of action of atypical antipsychotic drugs. Implication for novel therapeutic strategies for schizophrenia., Schizophr. Res., 4, 21, 10.1016/0920-9964(91)90030-U
Dewey S.T., 1995, Serotonergic modulation of striatal dopamine measured with positron emission tomography (PET) and in vivo microdialysis., J. Neurosci., 15, 821, 10.1523/JNEUROSCI.15-01-00821.1995
Di Giovanni G., 1997, Selective blockade of serotonin2c receptors enhances mesostriatal and mesolimbic dopaminergic function. (Abstr.), Trends Neurosci., 20, 9
Duxon M.S., 1995, Expression of 5‐HT2B receptor protein in the rat., Br. J. Pharmacol., 115, 105P
Kelland M.D., 1990, Serotonergic afferent regulation of the basic physiology and pharmacological responsiveness of nigrostriatal dopamine neurons., J. Pharmacol. Exp. Ther., 253, 803
Lejeune F., 1997, Serotonin (5‐HT2C) receptors inhibit the activity of mesocortical and mesolimbic dopaminergic pathways : a combined dialysis and electrophysiological analysis., Soc. Neurosci. Abstr., 23, 975
Leysen J.E., 1985, Receptor‐binding properties in vitro and in vivo of ritanserin, a very potent and long acting serotonin S2 antagonist., Mol. Pharmacol., 27, 600
Meltzer H.Y., 1991, Effects of antipsychotic drugs on serotonin receptors., Pharmacol. Rev., 43, 587
OffordS.J.(1998)M100907 a highly selective 5‐HT2Aantagonist for treatment of schizophrenia : early indication of safety and clinical activity in schizophrenic patients (Abstr.) inXXIst Collegium Internationale Neuro‐Psychopharmacologicum Congress Glasgow PT10052. Cambridge University Press.
PaxinosG.&WatsonC.(1986)The Rat Brain in Stereotaxic Coordinates 2nd edit. Academic Press Orlando.
Prisco S., 1994, Serotonin‐dopamine interaction in the rat ventral tegmental area : an electrophysiological study in vivo., J. Pharmacol. Exp. Ther., 271, 83
Rinaldi‐Carmona M., 1992, Biochemical and pharmacological properties of SR 46349B, a new potent and selective 5‐hydroxytryptamine2 receptor antagonist., J. Pharmacol. Exp. Ther., 262, 759
Schmidt C.J., 1996, Regional effects of MK‐801 on dopamine release : effects of competitive NMDA or 5‐HT2A antagonists receptor blockade., J. Pharmacol. Exp. Ther., 277, 1541
Schreiber R., 1995, 1‐(2,5‐Dimethoxy‐4‐iodophenyl)‐2‐aminopropane)‐induced head‐twitches in the rat are mediated by 5‐hydroxytryptamine (5‐HT)2A receptors : modulation by novel 5‐HT2A/C antagonists, D1 antagonists and 5‐HT1A agonists., J. Pharmacol. Exp. Ther., 273, 101
Shi W., 1995, Ritanserin, a 5‐HT2A/2C antagonist, reverses direct dopamine agonist‐induced inhibition of midbrain dopamine neurons., J. Pharmacol. Exp. Ther., 274, 735
Sorensen S.M., 1993, Characterization of the 5‐HT2 receptor antagonist MDL 100,907 as a putative atypical antipsychotic : behavioral, electrophysiological and neurochemical studies., J. Pharmacol. Exp. Ther., 266, 684